FR256F - New drug, in particular for the treatment of disorders of protein anabolism, manifestations of hypoandrogenism and hyperfolliculin. - Google Patents

New drug, in particular for the treatment of disorders of protein anabolism, manifestations of hypoandrogenism and hyperfolliculin.

Info

Publication number
FR256F
FR256F FR127218A FR127218A FR256F FR 256 F FR256 F FR 256F FR 127218 A FR127218 A FR 127218A FR 127218 A FR127218 A FR 127218A FR 256 F FR256 F FR 256F
Authority
FR
France
Prior art keywords
hyperfolliculin
hypoandrogenism
manifestations
disorders
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR127218A
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR54503A external-priority patent/FR5422M/fr
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Priority to FR127218A priority Critical patent/FR256F/en
Priority to FR137029A priority patent/FR273F/fr
Application granted granted Critical
Publication of FR256F publication Critical patent/FR256F/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
FR127218A 1965-12-23 1967-11-07 New drug, in particular for the treatment of disorders of protein anabolism, manifestations of hypoandrogenism and hyperfolliculin. Expired FR256F (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR127218A FR256F (en) 1965-12-23 1967-11-07 New drug, in particular for the treatment of disorders of protein anabolism, manifestations of hypoandrogenism and hyperfolliculin.
FR137029A FR273F (en) 1965-12-23 1968-01-23

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR43566 1965-12-23
FR54503A FR5422M (en) 1965-12-23 1966-03-22
FR127218A FR256F (en) 1965-12-23 1967-11-07 New drug, in particular for the treatment of disorders of protein anabolism, manifestations of hypoandrogenism and hyperfolliculin.

Publications (1)

Publication Number Publication Date
FR256F true FR256F (en) 1969-04-21

Family

ID=39830200

Family Applications (1)

Application Number Title Priority Date Filing Date
FR127218A Expired FR256F (en) 1965-12-23 1967-11-07 New drug, in particular for the treatment of disorders of protein anabolism, manifestations of hypoandrogenism and hyperfolliculin.

Country Status (1)

Country Link
FR (1) FR256F (en)

Similar Documents

Publication Publication Date Title
FR3069M (en) New drug, in particular for the treatment of protein anabolic disorders.
FR3851M (en) New drug in particular for the treatment of hypercholesterolemia and the resulting disorders.
FR1215M (en) New drug, in particular for the treatment of disorders due to hyperestrogenia or hypoandrogenia.
FR1958M (en) New drug in particular for the treatment of andropause, senescence and disorders of protein anabolism and cell building.
FR2963M (en) New drug, in particular for the treatment of protein anabolic disorders.
FR256F (en) New drug, in particular for the treatment of disorders of protein anabolism, manifestations of hypoandrogenism and hyperfolliculin.
FR2739M (en) New drug, in particular for the treatment of blood coagulability disorders.
FR3532M (en) New drug, in particular for the treatment of hypercholesterolemia and the resulting disorders.
FR1780M (en) New drug in particular for the treatment of disorders of protein anabolism.
FR3066M (en) New drug, in particular for the treatment of postprandial or chronic hyperlipemia.
FR3395M (en) New drug, in particular for the treatment of neurodepressive states and anxiety psychoses.
FR3031M (en) New drug in particular for the treatment of hypercholesterolemia and the resulting disorders.
FR3269M (en) New drug, in particular for the treatment of protein anabolic disorders.
FR2913M (en) New drug, in particular for the treatment of protein anabolic disorders.
FR3009M (en) New drug in particular for the treatment of protein anabolism and disorders due to hyperfolliculinia.
FR1857M (en) New drug in particular for the treatment of diseases of viral origin.
FR2576M (en) New drug, in particular for the treatment of blood coagulability disorders.
FR1489M (en) 4,4 'substituted diphenlysulfones and pharmaceutical preparations thereof for the treatment of viral diseases.
FR3096M (en) New drug in particular for the treatment of states of adynamia.
FR2789M (en) New drug in particular for the treatment of hypercholesterolemia and the resulting disorders.
FR2413M (en) New drug, in particular for the treatment of inflammatory and painful manifestations.
FR314M (en) New drug in particular for the treatment of disorders of protein anabolism and cell building.
FR15M (en) New drug in particular for the treatment of disorders of protein anabolism and cell building.
FR1204M (en) New drug, in particular for the treatment of chronic or post-prandial hyperlipemia.
FR3641M (en) New drug in particular for the treatment of states of adynamia.